Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on April 22, 2008, primarily to report its financial results for the first quarter of 2008 via an attached press release (Exhibit 99.1). While most of the press release is furnished and not deemed "filed" under the Exchange Act, key sections concerning the company's financial performance are subject to these reporting requirements. Investors should note that this filing serves as the official channel for disseminating these crucial quarterly financial updates.
Key Highlights
- 1Edwards Lifesciences reported its first quarter 2008 financial results on April 22, 2008.
- 2The results were disclosed through a press release filed as Exhibit 99.1 to the 8-K.
- 3Certain portions of the press release, specifically the first two paragraphs and pages 6-10, are deemed "filed" for purposes of the Securities Exchange Act of 1934.
- 4The filing does not contain detailed financial statements or management's discussion and analysis within the 8-K itself, but directs investors to the press release for this information.
- 5The Chief Financial Officer, Thomas M. Abate, signed the filing, indicating the financial results have been formally acknowledged by the company's leadership.
Frequently Asked Questions
The primary purpose of this 8-K filing is to officially report Edwards Lifesciences' financial results for the first quarter of 2008. This is done by attaching a press release that contains the detailed financial information.
The detailed financial results for the first quarter of 2008 can be found in the press release attached as Exhibit 99.1 to this 8-K filing.
No, not all information is considered 'filed'. Only the information contained in the first two paragraphs of Exhibit 99.1 and pages 6 through 10 of the press release are deemed 'filed' under the Securities Exchange Act of 1934. The rest is furnished.
The filing was signed by Thomas M. Abate, who serves as the Corporate Vice President, Chief Financial Officer, and Treasurer of Edwards Lifesciences Corporation.